Special Issue

Hairy Cell Leukemia and Related Disorders—Current Progress in Biology and Treatment

Message from the Guest Editors

Classic hairy cell leukemia (HCL) is a rare B-cell leukemia with an incidence of 0.3 per 100,000 yearly, characterized by pancytopenia, splenomegaly, and infection susceptibility. HCL-variant (HCLv) shares features with both classical HCL and B-cell prolymphocytic leukemia, and alongside other HCL-like diseases, is closely related to splenic lymphomas. The WHO's fifth edition classifies these as splenic B-cell lymphoma/leukemia with prominent nucleoli. Treatment for classic HCL primarily involves purine nucleoside analogs (cladribine, pentostatin), while BRAF inhibitors (vemurafenib, dabrafenib) are effective in relapsed cases. New therapies, including BTK inhibitors and venetoclax, are under investigation. HCLv treatment remains challenging, and despite advances, these diseases are incurable, highlighting the need for deeper biological understanding and novel therapies. For this Special Issue of *Cancers*, we welcome original research and review articles that provide an overview of the most recent advances and future challenges for the diagnosis and treatment of classic HCL and related disorders, including HCL-variant, SDRPL and other diseases.

Guest Editors

Prof. Dr. Ewa Robak
Department of Dermatology, Medical University of Lodz, Lodz, Poland
Prof. Dr. Tadeusz Robak
Department of Hematology, Medical University of Lodz, Lodz, Poland

Deadline for manuscript submissions

closed (30 November 2024)

Cancers

an Open Access Journal by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed

mdpi.com/si/199196

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

mdpi.com/journal/cancers

Cancers

an Open Access Journal by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed

mdpi.com/journal/cancers

About the Journal

Message from the Editor-in-Chief

Cancers (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok
Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)